UNSPSC 51352434: Ethinyl estradiol/methyltestosterone/multivitamins

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class VT809. This VA Drug Class (VT809) classifies this compound as belonging to the group VITAMIN COMBINATIONS, OTHER.

UNSPSC 51352434 Ethinyl estradiol/methyltestosterone/multivitamins is a Commodity code covering branded and generic hormonal and multivitamin pharmaceutical products sold through state and local health benefit programs, pharmacy benefit networks, and cooperative purchasing alliances. State and local buying under this code spans health and human services agencies managing Medicaid and employee health plans, departments of administration overseeing purchasing cooperatives, and multi-state consortia negotiating volume pricing for distributed pharmaceutical inventories. Work solicited includes manufacturer direct contracting for prescription fulfillment, product supply agreements through authorized pharmaceutical wholesalers, compliance certification for current good manufacturing practices and drug supply chain security, pricing and product specification submissions with National Drug Codes and packaging details, and maintenance of chargeback systems with wholesale distribution partners.

Recent activity concentrates in the Southwest and Upper Midwest. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs and therapeutic pharmacy initiative implementation outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 with a March 26, 2026 response deadline for multi-source generic pharmaceuticals and over-the-counter products to be supplied through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., with contract awards effective July 1, 2026. MMCAP's evaluation weights price competitiveness at 75 percent, fixed pricing at 10 percent, and administrative compliance at 15 percent combined; vendors must maintain $5 million commercial general liability coverage and contractual relationships with at least two of three authorized wholesalers. Both solicitations stress pricing flexibility, compliance with Food and Drug Administration requirements and the Drug Supply Chain Security Act, and electronic data interchange capability.